Signal Pharmaceuticals, Inc.

Recurium IP Holdings, LLC

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Sayee Gajanan Hegde

Kevin Duane Bunker

John J Sapienza

Peter Qinhua Huang

Patrick Papa

Deborah Mortensen

Veronique Plantevin-Krenitsky

Jason Parnes

Chad Daniel Hopkins

Ronald J Albers

Maria Mercedes Delgado Mederos

Steven Spencer Clareen

Eduardo Torres

Katerina Leftheris

Dehua Huang

Joshua Hansen

Matthew Daniel Correa

Joseph Robert Pinchman

Raj Kumar Raheja

Stephen Norris

Brandon Wade Whitefield

Brian Edwin Cathers

Sogole Bahmanyar

Deborah Helen Slee

Rakesh Kumar Sit

Andrew Antony Calabrese

Daniel Cashion

Maria Mercedes Delgado

Yoshitaka Satoh

Guobao Zhang

Adam Kois

Jennifer Riggs

Marianne Sloss

Brydon L Bennett

Kimberly Schwarz

Jeffrey McKenna

Robert Hilgraf

Meg McCarrick

Kiran Sahasrabudhe

Jonathan Wright

Moorthy S S Palanki

Lisa Nadolny

Kevin Hughes

Leticia Ayala

Elise Sudbeck

Meg Mccarrick

Sunil Paliwal

Sunny Abraham

Ian Henderson

Ahmed Abdi Samatar

Andrew Graham Cole

Brant Clayton Boren

Hui Liu

Moorthy S Palanki

Andrew G Cole

Aditya Krishnan Unni

Fernando Donate

Jianhui Ma

Jiali Li

Marian Sloss

Ronald Albers

Stephen Tyson Norris

Kiram Sahasrabudhe

Marianne K Sloss

Moorthy Ss Palanki

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.

Estrogen receptor modulators

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer. 

Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER&#x3b1;).

Estrogen receptor modulators for treating mutants

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer. 

Provided herein are diaminopyrimidyl Compounds having the following structures: 

Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith

Provided herein are Heteroaryl Compounds having the following structure: 

Methods of treatment using heteroaryl compounds and compositions thereof

Provided herein are Aminopurine Compounds having the following structure: 

Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Heteroaryl compounds, compositions thereof, and methods of treatment therewith

Growing community of inventors

San Diego, CA, United States of America

Sayee Gajanan Hegde